Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Alzeca Biosciences’ ADx imaging technology shows positive results in early detection of Alzheimer’s

June 7, 2016 By Abigail Esposito

Alzeca ADiX

Alzeca Biosciences announced successful preliminary results for ADx, its novel, proprietary diagnostic imaging technology, designed to enable diagnosis of Alzheimer’s Disease for the first time on conventional Magnetic Resonance Imaging (MRI), providing results a decade or more before the onset of symptoms of cognitive decline.

Alzeca Biosciences announced successful preliminary results for ADx, its novel, proprietary diagnostic imaging technology, designed to enable diagnosis of Alzheimer’s Disease for the first time on conventional Magnetic Resonance Imaging (MRI), providing results a decade or more before the onset of symptoms of cognitive decline.

Successful development of ADx would make early and reliable Alzheimer’s testing available to millions, using scanning technology that is widely available, and at far lower cost and without the radiation of current Positron Emission Tomography (PET) scans. Earlier detection of Alzheimer’s could revolutionize the treatment of the disease and vastly improve the efficiency of clinical trials for new therapies by identifying appropriate candidates for participation.

Alzeca also is exploring the significant additional potential of the underlying platform of ADx, which can be modified to bind to different targets in the brain. With these modifications, the platform could be used to image and diagnose other serious neurodegenerative diseases, and ultimately be used as a drug delivery system for treating those conditions.

Initial tests yield strong results
In peer-reviewed studies, the ADx nanoparticle demonstrated the ability to carry a contrast agent for MR imaging with a targeted ligand across the blood-brain barrier to bind precisely to amyloid plaques in the brains of test mice. Researchers were then able to demonstrate those plaques using ordinary MR equipment. These results, along with successful preliminary toxicity studies, allow Alzeca to accelerate the development and testing of ADx, with the goal of beginning human clinical trials in 2018. In May, the company was awarded a $322,000 grant from the Alzheimer’s Drug Discovery Foundation to fund the next phase of testing of ADx in canine subjects.

Significant unmet need
More than 27 million people suffer from Alzheimer’s disease today, and it is the sixth leading cause of death in the U.S. By 2050, the disease could result in a $1.1 trillion annual cost to the U.S. healthcare system. Yet there is no cost-effective, readily available, reliable way to diagnose the disease before the onset of cognitive decline, which is when current Alzheimer’s therapies have traditionally been most effective.

ADx would not only confirm an Alzheimer’s diagnosis years before significant clinical impairment, but also allow physicians to rule out such a diagnosis, to ensure better management for aging patients. Misdiagnosed dementia patients not only receive the wrong therapies, but the cost of treating a misdiagnosed patient adds $12,000 to the annual cost of treatment.

Powerful technology
Alzeca’s innovative biodiagnostic platform is a nanoparticle that can carry an imaging marker or other “payload” and pass through the normally impenetrable blood-brain barrier. The outside of each nanoparticle is designed to bind precisely to specific target substances in the brain, delivering the payload to that target.

ADx is the first product based on the platform. ADx carries an MR imaging agent as its payload and through a ligand targets the amyloid plaques that are the hallmark of the onset of Alzheimer’s disease, developing ten or more years before cognitive impairment. Once ADx is bound to the plaques, beta-amyloid (the hallmark of the disease in its earliest stages), it can be imaged in high resolution using a standard MRI scan for the first time.

Superior modalities
MRI scans are radiation-free, far less costly and more readily available throughout the world compared with the only current alternative, a PET scan. PET scans cost two to five times more than MRI scans and require radioactive imaging agents that preclude routine use, while ADx would permit physicians to track the patient’s condition over time and even screen for the disease.

Alzeca Biosciences
www.alzeca.com

Related Articles Read More >

A screenshot showing blood samples enlarged with a microscope and annotated with AI
AI-powered scope developer says new FDA clearance opens the door for telehematology
MIT fluorescence brain implants
How fluorescent signals could allow for deeper sensor implants in the brain
GE Healthcare image illustrating contrast media uses
GE Healthcare says recovery in supply of contrast media is on the way
Würth Elektronik and Valens Semiconductor logos
Würth Elektronik, Valens Semiconductor have a medical imaging offering

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech